Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Am J Transplant. 2009 Mar;9(3):452–462. doi: 10.1111/j.1600-6143.2008.02533.x

Figure 5.

Figure 5

PS1145 treatment of alloreactive T-cells significantly reduces their capacity for GVHD lethality in primary host-type recipients. (A) 105 vehicle-cultured cells or PS1145 cultured (10 µM) cells recovered from B6 anti-bm12 day 7 from MLR cultures established with whole CD4+ T-cells or CD4+CD25− T-cells and injected into sublethally irradiated bm12 recipients (n=5 to 10/group). (B) 105 vehicle-cultured cells or PS1145-cultured (10 µM) cells recovered on Balb/c anti-B6 day 5 from MLR cultures established with whole CD25− T-cells and injected into sublethally irradiated CB6F1 SCID recipients (vehicle n=8, PS1145-treated n=16, p=9.24×10−7).